Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972436 | 0.82 | P2RY14 (0.36) | P2RY2P2RY4CYP3A4CYP2C9POLB | |
| SCHEMBL16125703 | 0.81 | CYP3A4 (0.41) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL14929281 | 0.80 | P2RY2 (0.40) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL17972423 | 0.78 | P2RY2 (0.44) | P2RY2P2RY4CYP3A4CYP2C9POLA1 | |
| SCHEMBL12939375 | 0.78 | P2RY2 (0.44) | P2RY2P2RY4CYP3A4CYP2C9POLA1 | |
| SCHEMBL800360 | 0.78 | CYP3A4 (0.41) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL15497742 | 0.77 | NT5E (0.40) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL18118969 | 0.77 | NT5E (0.40) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL10238945 | 0.76 | P2RY2 (0.36) | RNASE1P2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL17972479 | 0.75 | P2RY2 (0.40) | P2RY2P2RY4CYP2C9POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447132-B2 | Highly active nucleoside derivative for the treatment of HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | RNASE1 43/4885P2RY2 315/4885P2RY4 249/4885 |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | SLC28A1, SLC28A2, NUDT1 | RNASE1 49/4885P2RY2 1406/4885P2RY4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.